AU2002218262B2 - Treatment of gastrointestinal stromal tumors - Google Patents

Treatment of gastrointestinal stromal tumors Download PDF

Info

Publication number
AU2002218262B2
AU2002218262B2 AU2002218262A AU2002218262A AU2002218262B2 AU 2002218262 B2 AU2002218262 B2 AU 2002218262B2 AU 2002218262 A AU2002218262 A AU 2002218262A AU 2002218262 A AU2002218262 A AU 2002218262A AU 2002218262 B2 AU2002218262 B2 AU 2002218262B2
Authority
AU
Australia
Prior art keywords
salt
treatment
methyl
benzamide
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002218262A
Other languages
English (en)
Other versions
AU2002218262A1 (en
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J. Druker
Jonathan A. Fletcher
Michael C. Heinrich
Heikki Joensuu
Sandra Leta Silberman
David Tuveson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma AG
Original Assignee
Novartis Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002218262(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma AG filed Critical Novartis Pharma AG
Publication of AU2002218262A1 publication Critical patent/AU2002218262A1/en
Application granted granted Critical
Publication of AU2002218262B2 publication Critical patent/AU2002218262B2/en
Assigned to NOVARTIS AG, OREGON HEALTH & SCIENCE UNIVERSITY, DANA-FABER CANCER INSTITUTE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC reassignment NOVARTIS AG Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG Request for Assignment Assignors: DANA-FARBER CANCER INSTITUTE, NOVARTIS AG, OREGON HEALTH & SCIENCE UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
AU2002218262A 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors Expired AU2002218262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number Publication Date
AU2002218262A1 AU2002218262A1 (en) 2002-07-11
AU2002218262B2 true AU2002218262B2 (en) 2005-09-29

Family

ID=22920224

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002218262A Expired AU2002218262B2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors
AU1826202A Pending AU1826202A (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU1826202A Pending AU1826202A (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Country Status (25)

Country Link
US (1) US6958335B2 (enExample)
EP (1) EP1332137B1 (enExample)
JP (1) JP4386635B2 (enExample)
KR (1) KR100885129B1 (enExample)
CN (1) CN1276754C (enExample)
AT (1) ATE321556T1 (enExample)
AU (2) AU2002218262B2 (enExample)
BR (1) BRPI0114870B8 (enExample)
CA (1) CA2424470C (enExample)
CY (1) CY1105055T1 (enExample)
CZ (1) CZ303944B6 (enExample)
DE (1) DE60118430T2 (enExample)
DK (1) DK1332137T3 (enExample)
ES (1) ES2260317T3 (enExample)
HU (1) HU229106B1 (enExample)
IL (2) IL155029A0 (enExample)
MX (1) MXPA03003703A (enExample)
NO (1) NO324948B1 (enExample)
NZ (1) NZ525254A (enExample)
PL (1) PL209733B1 (enExample)
PT (1) PT1332137E (enExample)
RU (1) RU2301066C2 (enExample)
SK (1) SK287335B6 (enExample)
WO (1) WO2002034727A2 (enExample)
ZA (1) ZA200302155B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PL392652A1 (pl) * 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
WO2003002106A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
EP1401412A2 (en) * 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
JP2004537537A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
US7678805B2 (en) * 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
JP2005507917A (ja) * 2001-09-20 2005-03-24 アブ サイエンス 育毛を促進するためのチロシンキナーゼ阻害剤の使用方法
CA2460845A1 (en) * 2001-09-20 2003-03-27 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
DK1478380T3 (da) * 2002-02-27 2006-11-27 Ab Science Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20080096864A1 (en) * 2003-09-19 2008-04-24 Sasa Dimitrijevic Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
KR20210043016A (ko) 2011-03-04 2021-04-20 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6525072B1 (en) * 1998-08-31 2003-02-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (de) * 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidinderivate und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
BR0114870A (pt) 2004-02-17
NZ525254A (en) 2006-02-24
NO20031833L (no) 2003-04-24
JP4386635B2 (ja) 2009-12-16
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
PL209733B1 (pl) 2011-10-31
KR20030051656A (ko) 2003-06-25
CN1622808A (zh) 2005-06-01
HUP0301512A2 (hu) 2003-11-28
IL155029A0 (en) 2003-10-31
SK287335B6 (sk) 2010-07-07
WO2002034727A2 (en) 2002-05-02
NO324948B1 (no) 2008-01-07
CZ303944B6 (cs) 2013-07-10
BRPI0114870B8 (pt) 2021-05-25
SK5182003A3 (en) 2004-02-03
CN1276754C (zh) 2006-09-27
BRPI0114870B1 (pt) 2020-06-16
EP1332137B1 (en) 2006-03-29
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
RU2301066C2 (ru) 2007-06-20
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
ES2260317T3 (es) 2006-11-01
US20040023976A1 (en) 2004-02-05
CZ20031152A3 (en) 2004-04-14
DE60118430T2 (de) 2006-10-26
MXPA03003703A (es) 2005-01-25
DE60118430D1 (de) 2006-05-18
PL362148A1 (en) 2004-10-18
IL155029A (en) 2009-09-22
EP1332137A2 (en) 2003-08-06
KR100885129B1 (ko) 2009-02-23
ZA200302155B (en) 2004-04-22
CY1105055T1 (el) 2010-03-03
ATE321556T1 (de) 2006-04-15
HK1058193A1 (en) 2004-05-07
CA2424470C (en) 2009-06-09
HU229106B1 (en) 2013-07-29
DK1332137T3 (da) 2006-07-17
AU1826202A (en) 2002-05-06

Similar Documents

Publication Publication Date Title
AU2002218262B2 (en) Treatment of gastrointestinal stromal tumors
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
AU2013203637B2 (en) Combination therapy for proliferative disorders
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
CA3137204A1 (en) Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcoma
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
EP2651414A1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
TWI287986B (en) Use of Epothilones for the treatment of the carcinoid syndrome
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
HK1058193B (en) Treatment of gastrointestinal stromal tumors
EP3572082A1 (en) Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug
TWI676477B (zh) 苯并咪唑衍生物用於夜間酸突破的用途
DiBenedetto Jr et al. Phase II Study of Melphalan in Colorectal Carcinoma ¹
EP1474148A1 (en) Treatment of neuroblastoma

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-APPLICANT DANA- FABER CANCER INSTITUTE, OREGON HEALTH & SCIENCE UNIVERSITY AND THE BRIGHAM AND WOMEN'S HOSPITAL, INC

FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 20, NO 3, PAGE(S) 232 UNDER THE HEADING AMENDMENTS, SECTION 104 - AMENDMENTS MADE UNDER THE NAMES NOVARTIS AG, DANA-FABER CANCER INSTITUTE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC. AND OREGON HEALTH & SCIENCE UNIVERSITY, APPLICATION NO. 2002218262, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO READ DANA-FARBER CANCER INSTITUTE.

PC Assignment registered

Owner name: NOVARTIS PHARMA AG

Free format text: FORMER OWNER WAS: OREGON HEALTH & SCIENCE UNIVERSITY; DANA-FARBER CANCER INSTITUTE; NOVARTIS AG; THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired